U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H22N4O.2ClH
Molecular Weight 371.305
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MINAPRINE HYDROCHLORIDE

SMILES

Cl.Cl.CC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3

InChI

InChIKey=GNUCGROXDZMCJI-UHFFFAOYSA-N
InChI=1S/C17H22N4O.2ClH/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-11-22-12-10-21;;/h2-6,13H,7-12H2,1H3,(H,18,20);2*1H

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C17H22N4O
Molecular Weight 298.3828
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Minaprine, a psychotropic drug, which was effective in the treatment of various depressive states. This drug was withdrawn because of the serious side effect. It was found, that minaprine inhibited the following enzymes, acetylcholinesterase and monoamine oxidase (MOA) A. It also binds to dopamine D1 and D2 receptors. Experiments on rodents also have revealed that minaprine suppressed the inhibitory effect of hydroxytryptamine (5-HT) on dopamine (DA) release via the inhibition of 5-HT binding at the 5-HT2 receptor on the nerve terminal.

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 85.0 µM [IC50]
Agonist
2752
 17.0 µM [Ki]
Inhibitor
8504
 1.0 mM [IC50]
Agonist
2752
Antagonist
2849
PubMed

PubMed

TitleDatePubMed
Molecular properties and CYP2D6 substrates: central nervous system therapeutics case study and pattern analysis of a substrate database.
2009-11
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
2007-09-04
3-Benzidino-6(4-chlorophenyl) pyridazine blocks delayed rectifier and transient outward potassium current in acutely isolated rat hippocampal pyramidal neurons.
2006-07-10
Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.
2003-12-01
Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress.
2002-11-09
Pharmacological evaluation of minaprine dihydrochloride, a new psychotropic drug.
1982

Sample Use Guides

In Vivo Use Guide
minaprine 100 mg, 200 mg or 300 mg day-1 . The drug was administered for 6 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:09:07 GMT 2025
Edited
by admin
on Mon Mar 31 18:09:07 GMT 2025
Record UNII
82Y7NT6DFT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MINAPRINE HYDROCHLORIDE
MART.   USAN  
USAN  
Official Name English
MINAPRINE DIHYDROCHLORIDE
MI   WHO-DD  
Preferred Name English
MINAPRINE DIHYDROCHLORIDE [MI]
Common Name English
MINAPRINE HCL
Common Name English
4-MORPHOLINEETHANAMINE, N-(4-METHYL-6-PHENYL-3-PYRIDAZINYL)-, DIHYDROCHLORIDE (2) 4-(2-((4-METHYL-6-PHENYL-3-PYRIDAZINYL)AMINO)ETHYL)MORPHOLINE DIHYDROCHLORIDE.
Systematic Name English
MINAPRINE HYDROCHLORIDE [MART.]
Common Name English
MINAPRINE HYDROCHLORIDE [JAN]
Common Name English
Minaprine dihydrochloride [WHO-DD]
Common Name English
NSC-305742
Code English
30038CB
Code English
30038-CB
Code English
MINAPRINE HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
Code System Code Type Description
USAN
X-74
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
NCI_THESAURUS
C80005
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
CHEBI
51040
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
DRUG BANK
DBSALT000305
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
ChEMBL
CHEMBL278819
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
FDA UNII
82Y7NT6DFT
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
EPA CompTox
DTXSID2045864
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
PUBCHEM
33254
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
NSC
305742
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
CAS
25953-17-7
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
SMS_ID
100000076071
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
RXCUI
236400
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY RxNorm
EVMPD
SUB14580MIG
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY
MERCK INDEX
m7551
Created by admin on Mon Mar 31 18:09:07 GMT 2025 , Edited by admin on Mon Mar 31 18:09:07 GMT 2025
PRIMARY Merck Index
Related Record Type Details
Structure of MINAPRINE
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of MINAPRINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966